DR. DAVID SILVERSTONE M.D.
Prescription History 1124098124
Ophthalmology in New Haven, CT


Quality Rating: 73.56 out of 100 score

NPI Status: Active since January 24, 2006

Contact Information

40 TEMPLE ST
SUITE 5B
NEW HAVEN, CT
ZIP 06510
Phone: (203) 789-2020
Fax: (203) 562-6028

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DAVID SILVERSTONE M.D., an active Ophthalmology specialist practicing in New Haven, CT. Our medical registry currently tracks 16 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 894 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 318 claims alone.


Alphagan P

Generic Formulation: Brimonidine TartrateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 12
30-Day Fills 25.1
Days Supply 726
CT State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills66.5
Peer Average Days Supply1,915
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,976.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$664.67

State Avg Cost Per Claim

$438.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 22
30-Day Fills 48.4
Days Supply 1,436
CT State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills103.7
Peer Average Days Supply3,031
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.0% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,120.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$323.64

State Avg Cost Per Claim

$74.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Brinzolamide

Generic Formulation: BrinzolamideSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 275
CT State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills63.6
Peer Average Days Supply1,898
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.6% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,259.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$205.39

State Avg Cost Per Claim

$342.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Brinzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Cyclosporine

Generic Formulation: CyclosporineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 40
30-Day Fills 54.0
Days Supply 1,575
CT State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills37.2
Peer Average Days Supply1,087
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 110.5% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,805.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$620.14

State Avg Cost Per Claim

$890.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 24
30-Day Fills 47.7
Days Supply 1,432
CT State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills96.5
Peer Average Days Supply2,882
Conservative Utilization

This provider writes prescriptions for this formulation 47.8% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $734.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.59

State Avg Cost Per Claim

$36.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 104
30-Day Fills 230.4
Days Supply 6,907
CT State Average Benchmarks
Peer Average Claims85.0
Peer Average 30-Day Fills196.0
Peer Average Days Supply5,869
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,383.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.92

State Avg Cost Per Claim

$40.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Fluorometholone

Generic Formulation: FluorometholoneSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 26
30-Day Fills 36.0
Days Supply 923
CT State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills56.0
Peer Average Days Supply1,466
Conservative Utilization

This provider writes prescriptions for this formulation 38.1% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,484.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$95.56

State Avg Cost Per Claim

$90.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Fluorometholone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 318
30-Day Fills 610.9
Days Supply 17,583
CT State Average Benchmarks
Peer Average Claims125.0
Peer Average 30-Day Fills242.5
Peer Average Days Supply6,977
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 154.4% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,279.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.89

State Avg Cost Per Claim

$28.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 20
30-Day Fills 37.4
Days Supply 1,120
CT State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills129.1
Peer Average Days Supply3,772
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.8% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,727.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$586.37

State Avg Cost Per Claim

$553.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Polymyxin B Sul-Trimethoprim

Generic Formulation: Polymyxin B Sulf/TrimethoprimSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 20
30-Day Fills 24.5
Days Supply 641
CT State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills53.3
Peer Average Days Supply1,332
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $168.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.45

State Avg Cost Per Claim

$8.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat bacterial infections (such as blepharitis, conjunctivitis) of the eye. It contains 2 antibiotics. Polymyxin B works by killing the bacteria. Trimethoprim works by stopping the growth of the bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Restasis

Generic Formulation: CyclosporineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 55
30-Day Fills 106.0
Days Supply 3,270
CT State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills98.0
Peer Average Days Supply2,902
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $64,351.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,170.03

State Avg Cost Per Claim

$1,318.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Restasis Multidose

Generic Formulation: CyclosporineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
CT State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills19.4
Peer Average Days Supply560
Conservative Utilization

This provider writes prescriptions for this formulation 26.7% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,672.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$697.53

State Avg Cost Per Claim

$869.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Simbrinza

Generic Formulation: Brinzolamide/Brimonidine TartSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 32
30-Day Fills 42.6
Days Supply 1,230
CT State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills56.2
Peer Average Days Supply1,649
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,057.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$283.04

State Avg Cost Per Claim

$276.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two medications used to treat high pressure in the eye due to glaucoma (open-angle glaucoma-type) or a certain other eye disease (ocular hypertension). Lowering high pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This product contains brinzolamide and brimonidine. These two medications work together to decrease the amount of fluid within the eye. Brinzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. Brimonidine belongs to a class of drugs known as alpha agonists. This product is not recommended for use in children younger than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 142
30-Day Fills 323.0
Days Supply 9,667
CT State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills155.6
Peer Average Days Supply4,614
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 108.8% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,785.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.70

State Avg Cost Per Claim

$40.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Tobramycin-Dexamethasone

Generic Formulation: Tobramycin/DexamethasoneSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 45
30-Day Fills 54.9
Days Supply 1,309
CT State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills34.8
Peer Average Days Supply594
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 36.4% more claims than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,004.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$66.77

State Avg Cost Per Claim

$80.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topical preparation of tobramycin and dexamethasone that is used for treating or preventing superficial bacterial infections of the eye.

Therapeutic Applications

This medication is used to treat or prevent eye infections. This medication contains two drugs. Tobramycin belongs to a class of drugs called aminoglycoside antibiotics. It works by stopping the growth of bacteria. Dexamethasone belongs to a class of drugs called corticosteroids. It works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Xiidra

Generic Formulation: LifitegrastSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
CT State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills54.8
Peer Average Days Supply1,647
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.3% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,974.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$747.92

State Avg Cost Per Claim

$1,168.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat dry eye disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DAVID SILVERSTONE M.D. provides transparency into local medical care patterns within New Haven, CT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.